Bio‑Techne (TECH) director adds 1,640 shares, 3,777 options
Bio‑Techne (TECH) director reported equity changes on 10/30/2025.
Rhea-AI Filing Summary
Bio‑Techne (TECH) director reported equity changes on 10/30/2025. The filing shows an acquisition of 1,640 shares of Common Stock at $0, bringing direct holdings to 15,411 shares. It also reports a new grant of 3,777 stock options with an exercise price of $60.96 and an expiration on 10/30/2035. According to the note, this option vests on the earlier of the one year anniversary of the grant date (10/30/2025) or the date of Bio‑Techne’s 2026 annual meeting of shareholders.
Positive
- None.
Negative
- None.
Insider Trade Summary
Grant/Award: 5,417 shares
Grant/Award
10 txns
Insider
KEEGAN JOSEPH D
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Options (Right to Buy) | 3,777 | $0.00 | $0.00 |
| Grant/Award | Common Stock | 1,640 | $0.00 | $0.00 |
| holding | Stock Options (Right to Buy) | -- | -- | -- |
| holding | Stock Options (Right to Buy) | -- | -- | -- |
| holding | Stock Options (Right to Buy) | -- | -- | -- |
| holding | Stock Options (Right to Buy) | -- | -- | -- |
| holding | Stock Options (Right to Buy) | -- | -- | -- |
| holding | Stock Options (Right to Buy) | -- | -- | -- |
| holding | Stock Options (Right to Buy) | -- | -- | -- |
| holding | Stock Options (Right to Buy) | -- | -- | -- |
Holdings After Transaction:
Stock Options (Right to Buy) — 51,381 contracts for 47,604 underlying shares (Direct);
Common Stock — 15,411 shares (Direct)
Footnotes (1)
- F1. This option vests on the earlier of the one year anniversary of the grant date (10/30/2025) or the date of Bio-Techne's 2026 annual meeting of shareholders.
FAQ
What did Bio‑Techne (TECH) disclose in this Form 4?
A director acquired 1,640 Common Stock at $0 and received 3,777 stock options on 10/30/2025.
What are the key terms of the newly granted stock options for TECH?
The new grant covers 3,777 options at an exercise price of $60.96, expiring on 10/30/2035.
When do the new Bio‑Techne options vest?
Per the note, they vest on the earlier of the one year anniversary of the grant date (10/30/2025) or Bio‑Techne’s 2026 annual meeting of shareholders.
What is the reporting person’s relationship to Bio‑Techne (TECH)?
The reporting person is a Director of Bio‑Techne.
Was the transaction reported as part of a 10b5‑1 plan?
The form includes the standard 10b5‑1 checkbox language; the excerpt does not indicate it was checked.
AI-generated analysis. How Rhea-AI works. Not financial advice.
